DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20183498

Pattern of management of febrile neutropenia among breast cancer patients treated with different chemotherapeutic regimens

Arun S., Seema P. Mohamedali, Anuradha M.

Abstract


Background: Breast cancer is one of the common malignancies in females. Chemotherapy with Adriamycin and Cyclophosphamide (AC) followed by the Docetaxel (AC-T, Regimen-I), AC followed by Docetaxel and Carboplatin (AC-T+Cr, Regimen-II) and AC followed by Docetaxel and Trastuzumab (AC-T+Tr, Regimen-III) are commonly given for treatment. These cause myelosuppression and febrile neutropenia and need necessary interventions.

Methods: This is a prospective open labelled observational comparative study to evaluate the antibiotic usage needed to treat sepsis following febrile neutropenia among breast cancer patients undergoing chemotherapy with regimen I, II and III. All patients received prophylactic Pegfilgrastim / Filgrastim. Antibiotics used and days in intensive care unit (ICU) in all the 8 cycles of chemotherapy were recorded. 38 patients in Regimen I, 40 patients in Regimen II and 46 patients in Regimen III completed the study and were included in the statistical analysis.

Results: In regimen II, following cycle 2 of chemotherapy, none of the patients needed antibiotic therapy. Antibiotic use was maximum, following cycle 1of chemotherapy in regimen I and III, maximum number of antibiotics prescribed were 7. Number of days of ICU care needed for regimen II patients following 3rd cycle of chemotherapy was 3.5±3.5 days. No ICU care was needed for regimen III patients, following cycles 2, 3 and for regimen II following cycle 7.

Conclusions: Febrile neutropenia produced by chemotherapy were effectively treated with intravenous antibiotics in ICU for an average of 2-3 days. No mortality was associated with febrile neutropenia and all patients were recovered.


Keywords


Antibiotic usage, Breast cancer, Chemotherapeutic regimens, Febrile neutropenia, ICU care

Full Text:

PDF

References


Burstein HJ, Harris JR, Morrow Monica. Malignant tumors of the breast. In: Vincent T. Devitha, Hellman, Steven A Rosenberg; Cancer principles and practice of oncology, 9th edition, Philadelphia, Wolters kluwer/Lippincott and Wilkins 2011;106:1401-44.

Hofstatter EW, Chung GG, Harris LN. Molecular biology of breast cancer. In: Vincent T. Devitha, Hellman, Steven A Rosenberg; Cancer principles and practice of oncology, 9th edition, Philadelphia, Wolters kluwer/Lippincott and Wilkins 2011;105:1392-1400.

Moulder S, Hortobagyi GN. Advances in the treatment of breast cancer. Clin Pharmacol Ther. 2008;83:26-36.

Chabner AB, Bertino J, Cleary J, Ortiz T, Lane A, Supko JG et al. Cytotoxic agents. In: Brunton LL, Chabner BA, Knollmann BC editors.Goodman and Gilman’s the pharmacological Basis of therapeutics, 12th edition, The McGraw hill companies new York 2011;61:1683-1715.

Wildiers H, Reiser M: Relative dose intensity of chemotherapy and its impact on outcome in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol. 2011;77:221-40.

Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, etal: Reduction by granulocyte colony -stimulating factor for fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Eng J Med.1991;325:164-170.

Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N etal, European organisation of Research and Treatment of Cancer (2011) 2010 update of EORTC guidelines for the use of granulocyte colony stimulating factor to reduce the incidence of febrile neutropenia in adult patients with lymph proliferative disorders and solid tumours. Eur J Cancer. 2010;47:8-32.

Tew KD, Reed E, Saif WM, Chu E, Abu-Khalaf MM, Harris LN. Pharmacology of Cancer therapeutics /chemotherapeutic agents In: Vincent T.Devitha, Hellman, Steven A Rosenberg; Cancer principles and practice of oncology, 9th edition, Philadelphia, Wolters kluwer/Lippincott and Wilkins. 2011;4(1):375-420.

Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas Figueroa LJ, et al. First and subsequent cycle use of Pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double blind, and placebo -controlled phase111 study. J Clin Oncol. 2005;23:1178-84.

Gea-Banacloche J, Segal BH. Infections in Cancer patients. In: Vincent T.Devitha, Hellman, Steven A Rosenberg; Cancer principles and practice of oncology, 9th edition, Philadelphia, Wolters kluwer/Lippincott and Wilkins 2011;19(156):2272-98.

Chu E, Devitha VT. Physicians cancer chemotherapy drug manual, 1st Indian edition, Wall Street Burlington, Jones and Bartett learning. 2013;442-49.

Canetta R, Rozencweig M, Carter SK. Carboplatin: The clinical spectrum to date. Cancer Treat Rev. 1985; 12(suppl A):125-36.

Van der Vijgh WJ. Clinical pharmacokinetics of Carboplatin. Clin Pharmacokinet. 1991; 21.

Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, et al. Primary Granulocyte Colony stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. J Clin Oncol. 2013;31:4290-6.

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant Trastuzumab in HER2-Positive Breast cancer. The N Eng J Med. 2011;365:1273-83.

Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, et al. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia. J Clin Oncol. 2013 Oct 28;31(34):4283-9.

Timmer-Bonte JN, de Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandi SA, Termeer A, et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol. 2005 Nov 1;23(31):7974-84.

Cullen M, Baijal S: Prevention of febrile neutropenia: Use of prophylactic antibiotics. Br J Cancer. 2009 (suppl 1); 101:S11-S14.

Chabner AB, Bertino J, Cleary J, Ortiz T, Lane A, Supko JG, et al. Cytotoxic agents. In: Brunton LL, Chabner BA, Knollmann BC editors.Goodman and Gilman’S the pharmacological Basis of therapeutics, 12th edition, The McGraw hill companies new York 2011;61:1683-1715.

Niederhuber JE, Armitage JO, Tepper JE, et al editors. Abeloff’s clinical oncology, 5th edition, Philadelphia, PA, Elsevier Saunders, 2014;29:434-484,91:1630-1691.

Nowak AK, Wilcken NR, Stockler MR, Hamilton A, Ghersi D. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol. 2004 Jun 1;5(6):372-80.

Aapro MS. European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (GCSF) Guidelines Working Party: EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433-53.

Greil R, Psenak O, Roila F, ESMO guidelines working group: hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol. 2008;19(suppl 2):116-118.

Cullen M, Baijal S. Prevention of febrile neutropenia: Use of prophylactic antibiotics. Br J Cancer. 2009; (suppl 1); 101:S11-S14.

Von Minckwitz G, Kümmel S, Du Bois A, Eiermann W, Eidtmann H, Gerber B, et al. Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol. 2007 Sep 9;19(2):292-8.